
Publishable Summary

The ethics team has had the task to monitor and study a set of central ethical issues in the AMYPAD project, including participant recruitment and disclosure of amyloid status, incidental findings, the framing of AD in research versus the public debate, and the dilemma for clinicians about whether to offer amyloid PET imaging in their practice. These topics are discussed in this report, which summarizes the lessons that can be learned from this experience. There were no major ethical concerns of the EAB. In the future, more work is needed to contextualize and disclose amyloid status.

For more information: info@amypad.org

Acknowledgement: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.



innovative
medicines
initiative